HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma

BACKGROUND: Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect the efficacy of TKI + IO. METHODS: Two...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xianglai, Zhang, Sihong, Wang, Ying, Zhu, Yanjun, Wang, Jiajun, Guo, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225196/
https://www.ncbi.nlm.nih.gov/pubmed/37031459
http://dx.doi.org/10.1002/cam4.5787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225196/
https://www.ncbi.nlm.nih.gov/pubmed/37031459
http://dx.doi.org/10.1002/cam4.5787

Ejemplares similares